Literature DB >> 28192376

Reasons for discontinuation of long-term opioid therapy in patients with and without substance use disorders.

Travis I Lovejoy1,2,3, Benjamin J Morasco1,2, Michael I Demidenko1, Thomas H A Meath1,4, Joseph W Frank5,6, Steven K Dobscha1,2.   

Abstract

Several factors may accelerate opioid discontinuation rates, including lack of information about the long-term effectiveness of opioids for chronic pain, heightened awareness about opioid-related adverse events, closer monitoring of patients for opioid-related aberrant behaviors, and greater restrictions around opioid prescribing. Rates of discontinuation may be most pronounced in patients deemed to be at "high risk." The purpose of this study was to compare reasons for discontinuation of long-term opioid therapy (LTOT) between patients with and without substance use disorder (SUD) diagnoses receiving care within a major U.S. health care system. This retrospective cohort study assembled a cohort of Veterans Health Administration patients prescribed opioid therapy for at least 12 consecutive months who subsequently discontinued opioid therapy for at least 12 months. From this cohort, we randomly selected 300 patients with SUD diagnoses and propensity score-matched 300 patients without SUD diagnoses. A comprehensive manual review of patients' medical records ascertained reasons for LTOT discontinuation. Most patients (85%) were discontinued as a result of clinician, rather than patient, decisions. For patients whose clinicians initiated discontinuation, 75% were discontinued because of opioid-related aberrant behaviors. Relative to patients without SUD diagnoses, those with SUD diagnoses were more likely to discontinue LTOT because of aberrant behaviors (81% vs 68%), most notably abuse of alcohol or other substances. This is the first study to document reasons for discontinuation of LTOT in a sample of patients with and without SUD diagnoses. Treatments that concurrently address SUD and chronic pain are needed for this high-risk population.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28192376     DOI: 10.1097/j.pain.0000000000000796

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  18 in total

1.  Reasons for Opioid Discontinuation and Unintended Consequences Following Opioid Discontinuation Within the TOPCARE Trial.

Authors:  Jawad M Husain; Marc LaRochelle; Julia Keosaian; Ziming Xuan; Karen E Lasser; Jane M Liebschutz
Journal:  Pain Med       Date:  2019-07-01       Impact factor: 3.750

2.  Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified.

Authors:  Jessica J Wyse; Benjamin J Morasco; Steven K Dobscha; Michael I Demidenko; Thomas H A Meath; Travis I Lovejoy
Journal:  J Opioid Manag       Date:  2018 Jul/Aug

3.  Evaluation of opioid discontinuation after non-orthopaedic surgery among chronic opioid users: a population-based cohort study.

Authors:  Naheed K Jivraj; Damon C Scales; Tara Gomes; Jennifer Bethell; Andrea Hill; Ruxandra Pinto; Duminda N Wijeysundera; Hannah Wunsch
Journal:  Br J Anaesth       Date:  2020-01-27       Impact factor: 9.166

4.  Opioid prescribing history prior to heroin overdose among commercially insured adults.

Authors:  Pooja Lagisetty; Kun Zhang; Rebecca L Haffajee; Lewei Allison Lin; Jason Goldstick; Rebecca Brownlee; Amy Bohnert; Marc R Larochelle
Journal:  Drug Alcohol Depend       Date:  2020-05-12       Impact factor: 4.492

5.  Medical Record Documentation About Opioid Tapering: Examining Benefit-to-Harm Framework and Patient Engagement.

Authors:  Michele Buonora; Hector R Perez; Jordan Stumph; Robert Allen; Shadi Nahvi; Chinazo O Cunningham; Jessica S Merlin; Joanna L Starrels
Journal:  Pain Med       Date:  2020-10-01       Impact factor: 3.750

6.  Correlates of Use and Perceived Effectiveness of Non-pharmacologic Strategies for Chronic Pain Among Patients Prescribed Long-term Opioid Therapy.

Authors:  Crystal C Lozier; Shannon M Nugent; Ning X Smith; Bobbi Jo Yarborough; Steven K Dobscha; Richard A Deyo; Benjamin J Morasco
Journal:  J Gen Intern Med       Date:  2018-05       Impact factor: 5.128

7.  Clinician Referrals for Non-opioid Pain Care Following Discontinuation of Long-term Opioid Therapy Differ Based on Reasons for Discontinuation.

Authors:  Travis I Lovejoy; Benjamin J Morasco; Michael I Demidenko; Thomas H A Meath; Steven K Dobscha
Journal:  J Gen Intern Med       Date:  2018-05       Impact factor: 5.128

8.  Opioid Discontinuation Among Patients Receiving High-Dose Long-Term Opioid Therapy in the Veterans Health Administration.

Authors:  Taeko Minegishi; Melissa M Garrido; Michael Stein; Elizabeth M Oliva; Austin B Frakt
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

9.  Clinician Response to Aberrant Urine Drug Test Results of Patients Prescribed Opioid Therapy for Chronic Pain.

Authors:  Benjamin J Morasco; Erin E Krebs; Melissa H Adams; Stephanie Hyde; Janet Zamudio; Steven K Dobscha
Journal:  Clin J Pain       Date:  2019-01       Impact factor: 3.442

10.  Substance Use Disorder Treatment Following Clinician-Initiated Discontinuation of Long-Term Opioid Therapy Resulting from an Aberrant Urine Drug Test.

Authors:  Shannon M Nugent; Steven K Dobscha; Benjamin J Morasco; Michael I Demidenko; Thomas H A Meath; Joseph W Frank; Travis I Lovejoy
Journal:  J Gen Intern Med       Date:  2017-06-09       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.